Exelixis (NASDAQ:EXEL) SVP Brenda Hefti Sells 18,669 Shares

Exelixis, Inc. (NASDAQ:EXEL) SVP Brenda Hefti sold 18,669 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $821,622.69. Following the completion of the sale, the senior vice president directly owned 96,512 shares of the company’s stock, valued at approximately $4,247,493.12. This represents a 16.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Exelixis Price Performance

Shares of NASDAQ EXEL opened at $44.47 on Thursday. Exelixis, Inc. has a 1 year low of $32.38 and a 1 year high of $49.62. The stock has a market capitalization of $11.55 billion, a P/E ratio of 16.05, a P/E/G ratio of 0.99 and a beta of 0.42. The company’s 50-day moving average is $43.77 and its 200 day moving average is $41.13.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.20. The business had revenue of $598.66 million for the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 EPS. Research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Analyst Ratings Changes

EXEL has been the subject of a number of research reports. Wells Fargo & Company increased their price objective on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Zacks Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Guggenheim cut shares of Exelixis from a “buy” rating to a “neutral” rating in a research report on Monday, November 3rd. Stifel Nicolaus upped their price objective on shares of Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a report on Wednesday, February 11th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $47.11.

Institutional Trading of Exelixis

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Motiv8 Investments LLC bought a new position in shares of Exelixis in the fourth quarter worth approximately $26,000. Richardson Financial Services Inc. raised its holdings in Exelixis by 95.1% in the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 292 shares during the last quarter. Anchor Investment Management LLC lifted its position in Exelixis by 500.0% in the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 500 shares in the last quarter. Acumen Wealth Advisors LLC purchased a new stake in Exelixis during the 4th quarter valued at $29,000. Finally, Root Financial Partners LLC purchased a new stake in Exelixis during the 3rd quarter valued at $28,000. 85.27% of the stock is currently owned by institutional investors.

Trending Headlines about Exelixis

Here are the key news stories impacting Exelixis this week:

• Neutral Sentiment: Summary: Multiple SEC Form 4 filings show insider sales totaling roughly $9 million across several executives and directors; the filings do not state the motivation (could be pre‑planned sales, diversification, or personal liquidity). CFO Christopher Senner filings
• Negative Sentiment: CFO Christopher J. Senner sold 34,278 shares on Feb 13 at an average $43.00 (~$1.47M) and 30,617 shares on Feb 17 at $43.67 (~$1.34M); combined reduction of ~3.18% and 3.04% of his holdings in separate filings. SEC filing
• Negative Sentiment: EVP Patrick J. Haley sold 67,814 shares on Feb 17 at an average $43.52 (~$2.95M), a ~15.08% cut to his stake. SEC filing
• Negative Sentiment: Director Bob Oliver sold 30,250 shares on Feb 13 at an average $43.81 (~$1.33M), reducing his position by ~58.9%. SEC filing
• Negative Sentiment: SVP Brenda Hefti sold 18,669 shares on Feb 18 at an average $44.01 (~$0.82M), trimming her holding by ~16.2%. SEC filing
• Negative Sentiment: Director Sue Gail Eckhardt sold 3,856 shares on Feb 13 at an average $43.79 (~$0.17M), an ~18.0% reduction of her stake. SEC filing

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.